DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing age-rage axis

Hormone and Metabolic Research

Volumn 47, Issue 4, 2015, Pages 253-258

  Ojima, A ^a   Matsui, T ^a   Nakamura, N ^a   Higashimoto, Y ^a   Ueda, S ^a   Fukami, K ^a   Okuda, S ^a   Yamagishi, S ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adipocytes; adiponectin; AGEs; aptamer; oxidative stress; RAGE

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; APTAMER; FRUCTOSE; GLUCOSE BLOOD LEVEL;

ADIPOCYTE; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SIZE; DIET; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT GAIN; WISTAR RAT;

ADIPOCYTES; ADIPONECTIN; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APTAMERS, NUCLEOTIDE; BLOOD GLUCOSE; CELL SIZE; DIET; FRUCTOSE; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; WEIGHT GAIN;

EID: 84929108572     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1385904     Document Type: Article

References (34)

1. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys: 2007; 48 147 157
2. Stitt A. W., Bucala R., Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci: 1997; 811 115 127
3. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol: 2011; 46 217 224
4. D'Agati V., Yan S. F., Ramasamy R., Schmidt A. M. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab: 2010; 21 50 56
5. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des: 2005; 11 2279 2299
6. Ward M. S., Fortheringham A. K., Cooper M. E., Forbes J. M. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol: 2013; 13 654 661
7. Gaens K. H., Goossens G. H., Niessen P. M., van Greevenbroek M. M., van der Kallen C. J., Niessen H. W., Rensen S. S., Buurman W. A., Greve J. W., Blaak E. E., van Zandvoort M. A., Bierhaus A., Stehouwer C. D., Schalkwijk C. G. N-{Varepsilon}-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol: 2014; 34 1199 1208
8. Song F., Hurtado Del Pozo C., Rosario R., Zou Y. S., Ananthakrishnan R., Xu X., Patel P. R., Benoit V. M., Yan S. F., Li H., Friedman R. A., Kim J. K., Ramasamy R., Ferrante A. W. Jr, Schmidt A. M. RAGE Regulates the Metabolic and Inflammatory Response to High Fat Feeding in Mice. Diabetes: 2014; 63 1948 1965
9. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets: 2011; 12 2096 20102
10. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des: 2008; 14 973 978
11. Abe R., Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des: 2008; 14 940 945
12. Unoki H., Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des: 2008; 14 987 989
13. Unoki H., Bujo H., Yamagishi S., Takeuchi M., Imaizumi T., Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract: 2007; 76 236 244
14. Unoki-Kubota H., Yamagishi S., Takeuchi M., Bujo H., Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett: 2010; 17 1177 1181
15. Tahara N., Yamagishi S., Matsui T., Takeuchi M., Nitta Y., Kodama N., Mizoguchi M., Imaizumi T. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther: 2012; 30 42 48
16. Ellington A. D., Szostak J. W. In vitro selection of RNA molecules that bind specific ligands. Nature: 1990; 346 818 822
17. Gragoudas E. S., Adamis A. P., Cunningham E. T., Feinsod M., Guyer D. R. Group VISiONCT Pegaptanib for neovascular age-related macular degeneration. N Engl J Med: 2004; 351 2805 2816
18. Jilma-Stohlawetz P., Gilbert J. C., Gorczyca M. E., Knöbl P., Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost: 2011; 106 539 547
19. Kaida Y., Fukami K., Matsui T., Higashimoto Y., Nishino Y., Obara N., Nakayama Y., Ando R., Toyonaga M., Ueda S., Takeuchi M., Inoue H., Okuda S., Yamagishi S. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes: 2013; 62 3241 3250
20. Ojima A., Oda E., Higashimoto Y., Matsui T., Yamagishi S. DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. Int J Cardiol: 2014; 171 443 446
21. Ojima A., Matsui T., Maeda S., Takeuchi M., Inoue H., Higashimoto Y., Yamagishi S. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest: 2014; 94 422 429
22. Hwang I. S., Ho H., Hoffman B. B., Reaven G. M. Fructose-induced insulin resistance and hypertension in rats. Hypertension: 1987; 10 512 516
23. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem: 2006; 281 20213 20220
24. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med: 2000; 6 114 125
25. Tahara N., Yamagishi S., Takeuchi M., Honda A., Tahara A., Nitta Y., Kodama N., Mizoguchi M., Kaida H., Ishibashi M., Hayabuchi N., Matsui T., Imaizumi T. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care: 2012; 35 2618 2625
26. Matsui T., Nishino Y., Ojima A., Maeda S., Tahara N., Yamagishi S. Pigment epithelium-derived factor improves metabolic derangements and ameliorates dysregulation of adipocytokines in obese type 2 diabetic rats. Am J Pathol: 2014; 184 1094 1103
27. Johnson R. J., Nakagawa T., Sanchez-Lozada L. G., Shafiu M., Sundaram S., Le M., Ishimoto T., Sautin Y. Y., Lanaspa M. A. Sugar uric acid, and the etiology of diabetes and obesity. Diabetes: 2013; 62 3307 3315
28. Feinman R. D., Fine E. J. Fructose in perspective. Nutr Metab (Lond): 2013; 10 45
29. Jia X., Wu L. Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem: 2007; 306 133 139
30. Soro-Paavonen A., Watson A. M., Li J., Paavonen K., Koitka A., Calkin A. C., Barit D., Coughlan M. T., Drew B. G., Lancaster G. I., Thomas M., Forbes J. M., Nawroth P. P., Bierhaus A., Cooper M. E., Jandeleit-Dahm K. A. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes: 2008; 57 2461 2469
31. Maeda S., Matsui T., Takeuchi M., Yamagishi S. Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property. Int J Cardiol: 2011; 146 264 266
32. Maeda S., Matsui T., Takeuchi M., Yamagishi S. Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. Int J Cardiol: 2011; 152 408 410
33. Mangge H., Almer G., Truschnig-Wilders M., Schmidt A., Gasser R., Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem: 2010; 17 4511 4520
34. Cruciani-Guglielmacci C., Vincent-Lamon M., Rouch C., Orosco M., Ktorza A., Magnan C. Early changes in insulin secretion and action induced by high-fat diet are related to a decreased sympathetic tone. Am J Physiol Endocrinol Metab: 2005; 288 E148 E154